Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Core Viewpoint - Larimar Therapeutics, Inc. has initiated a public offering of $75 million in common stock and pre-funded warrants, with an additional option for underwriters to purchase up to $11.25 million more, aimed at supporting the development of its lead compound, nomlabofusp, and for general corporate purposes [1][2]. Group 1 - Larimar is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its lead compound targeting Friedreich's ataxia [5]. - The proposed offering is subject to market conditions and may not be completed as planned [1]. - J.P. Morgan and Guggenheim Securities are acting as joint bookrunning managers for the offering [2]. Group 2 - The net proceeds from the offering will be used for research and development expenses, commercialization expenses, and working capital [2]. - The offering is being made under a shelf registration statement declared effective by the SEC on May 24, 2024 [3]. - A preliminary prospectus supplement will be filed with the SEC and will be available for free on their website [3].